Insmed Incorporated Website

Insmed Incorporated

NasdaqGS-INSM

Company Overview

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

  • Name

    Insmed Incorporated

  • CEO

    William H. Lewis

  • Website

    www.insmed.com

  • Sector

    Biotechnology

  • Year Founded

    1988

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

What's happening

Nov 5, 2025 - Dec 5, 2025

Insmed Inc Surges 13.2% Amid Key Developments and Strategic Endorsements

  • Mizuho maintains an "Outperform" rating for Insmed while raising its price target to $256.
  • The European Commission approved BRINSUPRI, marking a significant milestone for the company.
  • Billionaire Stanley Druckenmiller increased his stake in Insmed over four consecutive quarters.

Over the past month, Insmed Inc (INSM) experienced a notable increase of 13.2%, significantly outperforming the S&P 500's return of 1.3%. This performance reflects strong market sentiment driven by key developments and strategic updates from the company. Mizuho's decision to maintain an "Outperform" rating while raising its price target to $256 indicates confidence in Insmed’s growth potential, which has solidified investor optimism around its product pipeline.

A major highlight was the approval of BRINSUPRI (brensocatib) by the European Commission, making it the first treatment approved for non-cystic fibrosis bronchiectasis in patients with recurrent exacerbations. This development received positive attention on social media and contributed positively to stock performance throughout November. Anticipated sales projections for BRINSUPRI further fueled bullish sentiments among investors following favorable clinical trial results that demonstrated substantial efficacy.

Investor interest was also enhanced by high-profile endorsements; billionaire Stanley Druckenmiller increased his stake in INSM consistently over four quarters, showcasing his conviction in its long-term prospects within biotechnology stocks like Insmed. His investment strategy aligns with consistent revenue growth reported from both Arikayce and Brensocatib products.

Despite these positive trends, moments of bearish sentiment emerged due to insider selling activities that raised concerns about stock stability among some investors. Additionally, discussions surrounding challenges at critical price levels indicated caution within certain segments of the investor community regarding future movements.

Overall, INSM's robust performance highlights successful product approvals alongside strong institutional backing amid broader market conditions where it outperformed both sector benchmarks and general market indices by 11.9%. Specifically noted is that Insmed Inc outperformed the Health Care (XLV) sector by 7%.

NasdaqGS:INSM